Superficial spreading and nodular melanoma are distinct biological entities: A challenge to the linear progression model

Melanoma Research

Volumn 22, Issue 1, 2012, Pages 1-8

  Greenwald, Holly S ^a   Friedman, Erica B ^a   Osman, Iman ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

histological subtype; linear progression; melanoma; nodular melanoma; superficial spreading melanoma

Indexed keywords

MICRORNA; MITOGEN ACTIVATED PROTEIN KINASE;

CANCER GROWTH; CELL HETEROGENEITY; DISEASE ASSOCIATION; GENOMICS; HISTOPATHOLOGY; HUMAN; LINEAR REGRESSION ANALYSIS; MELANOMA; METASTASIS; MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SUPERFICIAL CANCER;

DISEASE PROGRESSION; HUMANS; LINEAR MODELS; MELANOMA; MODELS, BIOLOGICAL; NEOPLASM INVASIVENESS; PROGNOSIS; SKIN NEOPLASMS;

EID: 84855781390     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0b013e32834e6aa0     Document Type: Review

References (106)

1. Scolyer RA, Long GV, Thompson JF. Evolving concepts in melanoma classification and their relevance to multidisciplinary melanoma patient care. Mol Oncol 2011; 5:124-136.
2. McGovern V CR, Duncan C, Finaly-Jones L, Hardy E, Hicks J. Moles and malignant melanoma: Terminology and classification. Med J Australia 1967; 1:123-125.
3. Clark WH Jr, From L, Bernardino EA, Mihm MC. The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res 1969; 29:705-727.
4. International Agency for Research on Cancer. LeBoit PE, Burg G, Weedon D, Sarasin A editors. Pathology and genetics of skin tumours (IARC WHO classification of tumours). World Health Organization Classification of Tumours. 1st ed. Lyon: World Health Organization. p. 355.
5. McGovern VJ, Mihm MC Jr., Bailly C, Booth JC, Clark WH Jr., Cochran AJ, et al. The classification of malignant melanoma and its histologic reporting. Cancer 1973; 32:1446-1457.
6. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27:6199-6206.
7. Motoi N, Szoke J, Riely GJ, Seshan VE, Kris MG, Rusch VW, Gerald WL, Travis WD. Lung adenocarcinoma: Modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis. Am J Surg Pathol 2008; 32:810-827.
8. Eton O BL, Kim J, Prieto V, Davis D, Frazier ML, Diwan AH, et al. Phase II trial of imatinib mesylate (STI-571) in metastatic melanoma (MM). J Clin Oncol 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). 22, No 14S (July 15 Supplement), 2004: 7528.
9. Wyman K, Atkins MB, Prieto V, Eton O, McDermott DF, Hubbard F, et al. Multicenter phase II trial of high-dose imatinib mesylate in metastatic melanoma: Significant toxicity with no clinical efficacy. Cancer 2006; 106:2005-2011. (Pubitemid 43673217)
10. Weigelt B, Reis-Filho JS. Histological and molecular types of breast cancer: Is there a unifying taxonomy? Nature reviews. Clin Oncol 2009; 6:718-730.
11. Riely GJ, Pao W, Pham D, Li AR, Rizvi N, Venkatraman ES, et al. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res 2006; 12(3 Pt 1):839-844. (Pubitemid 43259866)
12. Mitsudomi T, Kosaka T, Endoh H, Horio Y, Hida T, Mori S, et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 2005; 23:2513-2520. (Pubitemid 47050841)
13. Jackman DM, Yeap BY, Sequist LV, Lindeman N, Holmes AJ, Joshi VA, et al. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res 2006; 12:3908-3914. (Pubitemid 44078074)
14. Chernoff KA, Bordone L, Horst B, Simon K, Twadell W, Lee K, et al. GAB2 amplifications refine molecular classification of melanoma. Clin Cancer Res 2009; 15:4288-4291.
15. Smalley KS, Contractor R, Nguyen TK, Xiao M, Edwards R, Muthusamy V, et al. Identification of a novel subgroup of melanomas with KIT/cyclindependent kinase-4 overexpression. Cancer Res 2008; 68:5743-5752.
16. Jaeger J, Koczan D, Thiesen HJ, Ibrahim SM, Gross G, Spang R, Kunz M. Gene expression signatures for tumor progression, tumor subtype, and tumor thickness in laser-microdissected melanoma tissues. Clin Cancer Res 2007; 13:806-815. (Pubitemid 46340353)
17. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, et al. Distinct sets of genetic alterations in melanoma. New Eng J Med 2005; 353:2135-2147. (Pubitemid 41653105)
18. Kwong L, Chin L,Wagner SN. Growth factors and oncogenes as targets in melanoma: lost in translation? Adv Dermatol 2007; 23:99-129.
19. Ackerman AB. Malignant melanoma: A unifying concept. Am J Dermatopathol 1980; 2:309-313.
20. Barnhill RL, Mihm MC Jr. The histopathology of cutaneous malignant melanoma. Sem Diagnos Pathol 1993; 10:47-75. (Pubitemid 23125016)
21. Rose AE, Poliseno L, Wang J, Clark M, Pearlman A, Wang G, et al. Integrative genomics identifies molecular alterations that challenge the linear model of melanoma progression. Cancer Res 2011; 71: 2561-2571.
22. Warycha MA, Christos PJ, Mazumdar M, Darvishian F, Shapiro RL, Berman RS, et al. Changes in the presentation of nodular and superficial spreading melanomas over 35 years. Cancer 2008; 113: 3341-3348.
23. Crocetti E, Caldarella A, Chiarugi A, Nardini P, Zappa M. The thickness of melanomas has decreased in central Italy, but only for thin melanomas, while thick melanomas are as thick as in the past. Melanoma Res 2010; 20: 422-426.
24. Geller AC, Elwood M, Swetter SM, Brooks DR, Aitken J, Youl PH, et al. Factors related to the presentation of thin and thick nodular melanoma from a population-based cancer registry in Queensland Australia. Cancer 2009; 115:1318-1327.
25. Poliseno L, Haimovic A, Hanniford D, Segura MF, Christos PJ, Shapiro RL, et al. Distinguishing between nodular and superficial spreading melanoma using specific microRNA alterations. J Clin Oncol 2011; 29 (suppl):abstract 8540.
26. Scatolini M, Grand MM, Grosso E, Venesio T, Pisacane A, Balsamo A, et al. Altered molecular pathways in melanocytic lesions. Int J Cancer 2010; 126:1869-1881.
27. Gaziel-Sovran A, Segura MF, Di Micco R, Collins MK, Hanniford D, Vega-Saenz de Miera E, et al. miR-30b/30d regulation of GalNAc transferases enhances invasion and immunosuppression during metastasis. Cancer Cell 2011; 20:104-118.
28. Kanoh M, Amoh Y, Tanabe K, Maejima H, Takasu H, Katsuoka K. Nestin is expressed in HMB-45 negative melanoma cells in dermal parts of nodular melanoma. J Dermatol 2010; 37:505-511.
29. Garbe C, Leiter U. Melanoma epidemiology and trends. Clin Dermatol 2009; 27:3-9.
30. Baumert J, Schmidt M, Giehl KA, Volkenandt M, Plewig G, Wendtner C, Schmid-Wendtner MH. Time trends in tumour thickness vary in subgroups: Analysis of 6475 patients by age, tumour site and melanoma subtype. Melanoma Res 2009; 19:24-30.
31. Demierre MF, Chung C, Miller DR, Geller AC. Early detection of thick melanomas in the United States: beware of the nodular subtype. Arch Dermatol 2005; 141:745-750. (Pubitemid 41001075)
32. Criscione VD, Weinstock MA. Melanoma thickness trends in the United States, 1988-2006. J Investigative Dermatol 2010; 130:793-797.
33. Lipsker DM, Hedelin G, Heid E, Grosshans EM, Cribier BJ. Striking increase of thin melanomas contrasts with stable incidence of thick melanomas. Arch Dermatol 1999; 135:1451-1456.
34. Richardson A, Fletcher L, Sneyd M, Cox B, Reeder AI. The incidence and thickness of cutaneous malignant melanoma in New Zealand 1994-2004. New Zealand Med J 2008; 121:18-26.
35. Crocetti E, Carli P. Unexpected reduction of mortality rates from melanoma in males living in central Italy. Eur J Cancer 2003; 39:818-821. (Pubitemid 36315999)
36. Tejera-Vaquerizo A, Mendiola-Fernandez M, Fernandez-Orland A, Herrera-Ceballos E. Thick melanoma: The problem continues. JEADV 2008; 22:575-579.
37. Linos E, Swetter SM, Cockburn MG, Colditz GA, Clarke CA. Increasing burden of melanoma in the United States. J Investigative Dermatol 2009; 129:1666-1674.
38. Chamberlain AJ, Fritschi L, Kelly JW. Nodular melanoma: Patients' perceptions of presenting features and implications for earlier detection. J Am Acad Dermatol 2003; 48:694-701. (Pubitemid 36583278)
39. Kelly JW, Chamberlain AJ, Staples MP, McAvoy B. Nodular melanoma: no longer as simple as ABC. Aus Fam Phys 2003; 32:706-709.
40. Rigel DS, Friedman RJ, Kopf AW, Polsky D. ABCDE: An evolving concept in the early detection of melanoma. Arch Dermatol 2005; 141:1032-1034. (Pubitemid 46165528)
41. Demierre MF. Epidemiology and prevention of cutaneous melanoma. Curr Treat Opt Oncol 2006; 7:181-186.
42. Friedlander P, Hodi FS. Advances in targeted therapy for melanoma. Clin Adv Hematol Oncol 2010; 8:619-627.
43. Edlundh-Rose E, Egyhazi S, Omholt K, Mansson-Brahme E, Platz A, Hansson J, Lundeberg J. NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: A study based on mutation screening by pyrosequencing. Melanoma Res 2006; 16:471-478. (Pubitemid 44934704)
44. Saldanha G, Potter L, Daforno P, Pringle JH. Cutaneous melanoma subtypes show different BRAF and NRAS mutation frequencies. Clin Cancer Res 2006; 12:4499-4505. (Pubitemid 44297798)
45. Ball NJ, Yohn JJ, Morelli JG, Norris DA, Golitz LE, Hoeffler JP. Ras mutations in human melanoma: A marker of malignant progression. J Investigative Dermatol 1994; 102:285-290.
46. van Elsas A, Zerp S, van der Flier S, Kruse-Wolters M, Vacca A, Ruiter DJ,Schrier P. Analysis of N-ras mutations in human cutaneous melanoma: Tumor heterogeneity detected by polymerase chain reaction/single-stranded Conformation polymorphism analysis. Recent Res Cancer Res 1995; 139:57-67
47. van't Veer LJ, Burgering BM, Versteeg R, Boot AJ, Ruiter DJ, Osanto S, et al. N-ras mutations in human cutaneous melanoma from sun-exposed body sites. Mol Cell Biol 1989; 9:3114-3116. (Pubitemid 19163079)
48. Albino AP, Nanus DM, Mentle IR, Cordon-Cardo C, McNutt NS, Bressler J, Andreeff M. Analysis of ras oncogenes in malignant melanoma and precursor lesions: Correlation of point mutations with differentiation phenotype. Oncogene 1989; 4:1363-1374. (Pubitemid 19273392)
49. Albino AP, Le Strange R, Oliff AI, Furth ME, Old LJ. Transforming ras genes from human melanoma: A manifestation of tumour heterogeneity? Nature 1984; 308:69-72. (Pubitemid 14130934)
50. Barbacid M. ras genes. Ann Rev Biochem 1987; 56:779-827.
51. Omholt K, Platz A, Kanter L, Ringborg U, Hansson J. NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Clin Cancer Res 2003; 9:6483-6488. (Pubitemid 38031837)
52. Reifenberger J, Knobbe CB, Sterzinger AA, Blaschke B, Schulte KW, Ruzicka T, Reifenberger G. Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas. Int J Cancer 2004; 109:377-384. (Pubitemid 38252766)
53. Lee JH, Choi JW, Kim YS. Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: A meta-analysis. Br J Dermatol 2011; 164:776-784.
54. Jafari M, Papp T, Kirchner S, Diener U, Henschler D, Burg G, Schiffmann D. Analysis of ras mutations in human melanocytic lesions: Activation of the ras gene seems to be associated with the nodular type of human malignant melanoma. J Cancer Res Clin Oncol 1995; 121:23-30.
55. Viros A, Fridlyand J, Bauer J, Lasithiotakis K, Garbe C, Pinkel D, Bastian BC. Improving melanoma classification by integrating genetic and morphologic features. PLoS Med 2008; 5:e120.
56. Broekaert SM, Roy R, Okamoto I, van den Oord J, Bauer J, Garbe C, et al. Genetic and morphologic features for melanoma classification. Pigment Cell Melanoma Res 2010; 23:763-770.
57. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417:949-954. (Pubitemid 34716871)
58. Pollock PM, Meltzer PS. A genome-based strategy uncovers frequent BRAF mutations in melanoma. Cancer Cell 2002; 2:5-7. (Pubitemid 41043982)
59. Brose MS, Volpe P, Feldman M, Kumar M, Rishi I, Gerrero R, et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 2002; 62:6997-7000. (Pubitemid 35424092)
60. Pollock PM, Harper UL, Hansen KS, Yudt LM, Stark M, Robbins CM, et al. High frequency of BRAF mutations in nevi. Nat Genet 2003; 33:19-20. (Pubitemid 36068675)
61. Liu W, Kelly JW, Trivett M, Murray WK, Dowling JP, Wolfe R, et al. Distinct clinical and pathological features are associated with the BRAF(T1799A(V600E)) mutation in primary melanoma. J Invest Dermatol 2007; 127:900-905. (Pubitemid 46434654)
62. Maldonado JL, Fridlyand J, Patel H, Jain AN, Busam K, Kageshita T, et al. Determinants of BRAF mutations in primary melanomas. J Natl Cancer Inst 2003; 95:1878-1890.
63. Thomas NE, Edmiston SN, Alexander A, Millikan RC, Groben PA, Hao H, et al. Number of nevi and early-life ambient UV exposure are associated with BRAF-mutant melanoma. Cancer Epidemiol Biomarkers Prev 2007; 16:991-997. (Pubitemid 46910102)
64. Sasaki Y, Niu C, Makino R, Kudo C, Sun C,Watanabe H, et al. BRAF point mutations in primary melanoma show different prevalences by subtype. J Invest Dermatol 2004; 123:177-183. (Pubitemid 38833479)
65. Lang J, MacKie RM. Prevalence of exon 15 BRAF mutations in primary melanoma of the superficial spreading, nodular, acral, and lentigo maligna subtypes. J Invest Dermatol 2005; 125:575-579.
66. Johnson N, Speirs V, Curtin NJ, Hall AG. A comparative study of genomewide SNP, CGH microarray and protein expression analysis to explore genotypic and phenotypic mechanisms of acquired antiestrogen resistance in breast cancer. Breast Cancer Res Treat 2008; 111:55-63. (Pubitemid 352009227)
67. Vanison C, Tanna N, Murthy AS. Comparative genomic hybridization for the diagnosis of melanoma. Eur J Plast Surg 2010; 33:45-48.
68. Bauer J, Bastian BC. Distinguishing melanocytic nevi from melanoma by DNA copy number changes: Comparative genomic hybridization as a research and diagnostic tool. Dermatol Ther 2006; 19:40-49.
69. Trolet J, Hupe P, Huon I, Lebigot I, Decraene C, Delattre O, et al. Genomic profiling and identification of high-risk uveal melanoma by array CGH analysis of primary tumors and liver metastases. Invest Ophthalmol. Vis. Sci. 2009; 50:2572-2580.
70. Mensink HW, Kilic E, Vaarwater J, Douben H, Paridaens D, de Klein A. Molecular cytogenetic analysis of archival uveal melanoma with known clinical outcome. Cancer Genet Cytogenet 2008; 181:108-111. (Pubitemid 351273423)
71. White JS, McLean IW, Becker RL, Director-Myska AE, Nath J. Correlation of comparative genomic hybridization results of 100 archival uveal melanomas with patient survival. Cancer Genet Cytogenet 2006; 170:29-39. (Pubitemid 44332561)
72. Hughes S, Damato BE, Giddings I, Hiscott PS, Humphreys J, Houlston RS. Microarray comparative genomic hybridisation analysis of intraocular uveal melanomas identifies distinctive imbalances associated with loss of chromosome 3. Br J Cancer 2005; 93:1191-1196. (Pubitemid 41670705)
73. Kabbarah O, Nogueira C, Feng B, Nazarian RM, Bosenberg M,Wu M, et al. Integrative genome comparison of primary and metastatic melanomas. PLoS One 2010; 5:e10770.
74. Balazs M, Adam Z, Treszl A, Begany A, Hunyadi J, Adany R. Chromosomal imbalances in primary and metastatic melanomas revealed by comparative genomic hybridization. Cytometry 2001; 46:222-232. (Pubitemid 32899792)
75. Liotta L, Petricoin E. Molecular profiling of human cancer. Nat Genet 2000; 1:48-56.
76. Ramaswamy S, Golub TR. DNA microarrays in clinical oncology. J Clin Oncol 2002; 20:1932-1941. (Pubitemid 34273286)
77. Liang P, Pardee AB. Analysing differential gene expression in cancer. Nat Rev Cancer 2003; 3:869-876. (Pubitemid 37376983)
78. Djuranovic S, Nahvi A, Green R. A parsimonious model for gene regulation by miRNAs. Science 2011; 331:550-553.
79. Kosik KS. MicroRNAs and cellular phenotypy. Cell 2010; 143:21-26.
80. Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009; 19: 92-105.
81. Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, Castle J, et al. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 2005; 433:769-773. (Pubitemid 40292988)
82. Neveu P, Kye MJ, Qi S, Buchholz DE, Clegg DO, Sahin M, et al. MicroRNA profiling reveals two distinct p53-related human pluripotent stem cell states. Cell Stem Cell 2010; 7:671-681.
83. Volinia S, Galasso M, Costinean S, Tagliavini L, Gamberoni G, Drusco A, et al. Reprogramming of miRNA networks in cancer and leukemia. Genome Res 2010; 20:589-599.
84. Landi MT, Zhao Y, Rotunno M, Koshiol J, Liu H, Bergen AW, et al. MicroRNA expression differentiates histology and predicts survival of lung cancer. Clin Cancer Res 2010; 16:430-441.
85. Jukic DM, Rao UN, Kelly L, Skaf JS, Drogowski LM, Kirkwood JM, Panelli MC. Microrna profiling analysis of differences between the melanoma of young adults and older adults. J Transl Med 2010; 8:27.
86. Dacic S, Kelly L, Shuai Y, Nikiforova MN. miRNA expression profiling of lung adenocarcinomas: Correlation with mutational status. Mod Pathol 2010; 23:1577-1582.
87. Chan E, Patel R, Nallur S, Ratner E, Bacchiocchi A, Hoyt K, et al. MicroRNA signatures differentiate melanoma subtypes. Cell Cycle 2011; 10:1845-1852.
88. Grichnik JM, Burch JA, Schulteis RD, Shan S, Liu J, Darrow TL, et al. Melanoma, a tumor based on a mutant stem cell? J Invest Dermatol 2006; 126:142-153. (Pubitemid 43336106)
89. Klein WM, Wu BP, Zhao S, Wu H, Klein-Szanto AJ, Tahan SR. Increased expression of stem cell markers in malignant melanoma. Mod Pathol 2007; 20:102-107. (Pubitemid 44967955)
90. van der Rhee JI, Krijnen P, Gruis NA, de Snoo FA, Vasen HF, Putter H, Kukutsch NA, Bergman W. Clinical and histologic characteristics of malignant melanoma in families with a germline mutation in CDKN2A. J Am Acad Dermatol 2011; 65:281-288.
91. Pavey SJ, Cummings MC, Whiteman DC, Castellano M, Walsh MD, Gabrielli BG, et al. Loss of p16 expression is associated with histological features of melanoma invasion. Melanoma Res 2002; 12:539-547. (Pubitemid 36042740)
92. Wang YL, Uhara H, Yamazaki Y, Nikaido T, Saida T. Immunohistochemical detection of CDK4 and p16INK4 proteins in cutaneous malignant melanoma. Br J Dermatol 1996; 134:269-275.
93. Reed JA, Loganzo F Jr., Shea CR,Walker GJ, Flores JF, Glendening JM, et al. Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression. Cancer Res 1995; 55:2713-2718.
94. Radhi JM. Malignant melanoma arising from nevi, p53, p16, and Bcl-2: Expression in benign versus malignant components. J Cutan Med Surg 1999; 3:293-297. (Pubitemid 29467298)
95. Funk JO, Schiller PI, Barrett MT, Wong DJ, Kind P, Sander CA. p16INK4a expression is frequently decreased and associated with 9p21 loss of heterozygosity in sporadic melanoma. J Cutan Pathol 1998; 25: 291-296. (Pubitemid 28318933)
96. Talve L, Sauroja I, Collan Y, Punnonen K, Ekfors T. Loss of expression of the p16INK4/CDKN2 gene in cutaneous malignant melanoma correlates with tumor cell proliferation and invasive stage. Int J Cancer 1997; 74:255-259. (Pubitemid 27321792)
97. Roth JM, Caunt M, Cretu A, Akalu A, Policarpio D, Li X, et al. Inhibition of experimental metastasis by targeting the HUIV26 cryptic epitope in collagen. Am J Pathol 2006; 168:1576-1586.
98. Xu J, Rodriguez D, Petitclerc E, Kim JJ, Hangai M, Moon YS, et al. Proteolytic exposure of a cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo. J Cell Biol 2001; 154:1069-1079. (Pubitemid 34286185)
99. Gagne PJ, Tihonov N, Li X, Glaser J, Qiao J, Silberstein M, et al. Temporal exposure of cryptic collagen epitopes within ischemic muscle during hindlimb reperfusion. Am J Pathol 2005; 167:1349-1359. (Pubitemid 41541421)
100. Cretu A, Roth JM, Caunt M, Akalu A, Policarpio D, Formenti S, et al. Disruption of endothelial cell interactions with the novel HU177 cryptic collagen epitope inhibits angiogenesis. Clin Cancer Res 2007; 13:3068-3078. (Pubitemid 46849584)
101. Ng B, Zakrzewski J,Warycha M, Christos PJ, Bajorin DF, Shapiro RL, et al. Shedding of distinct cryptic collagen epitope (HU177) in sera of melanoma patients. Clin Cancer Res 2008; 14:6253-6258.
102. Pavlick AC, Liebes L, Brooks P, Yoon J, Hamilton A, Yee H, et al. BAY 43-9006 (sorafenib-BAY) alters proliferation pathways and mutant specific-PCR (MS-PCR) improves detection of BRAF mutations in metastatic melanoma (MM). Clin Oncol 2007 ASCO Annual Meeting Proceedings Part I. 25 No. 18S (June 20 Supplement). 2007:8542.
103. Romano E, Schwartz GK, Chapman PB, Wolchock JD, Carvajal RD. Treatment implications of the emerging molecular classification system for melanoma. Lancet Oncol 2011; 12:913-922.
104. Carvajal RD, Antonescu CR, Wolchok JD, Chapman PB, Roman RA, Teitcher J, et al. KIT as a therapeutic target in metastatic melanoma. JAMA 2011; 305:2327-2334.
105. Guo J, Si L, Kong Y, Flaherty KT, Xu X, Zhu Y, et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol 2011; 29: 2904-2909.
106. Van Raamsdonk CD, Griewank KG, Crosby MB, Garrido MC, Vemula S, Wiesner T, et al. Mutations in GNA11 in uveal melanoma. N Engl J Med 2010; 363:2191-2199.